Quick Ebola vax development could assist with future outbreaks; GSK touts 'major' Synflorix label expansion;

> The rapid development of Merck's ($MRK) Ebola vaccine--which this week was reported to protect 100% of patients in a Phase III trial--could provide a model for addressing future outbreaks. More

> The Committee for Medicinal Products for Human Use (CHMP) granted GlaxoSmithKline's ($GSK) Synflorix a label expansion to include effectiveness data for protection against invasive pneumococcal disease and pneumonia and acute otitis media caused by the pneumococcus bacterium. Release

> BiondVax ($BVXV) reported that its universal flu vaccine candidate, administered in a Phase II trial 3 years ago, provided patients with increased immunogenicity against influenza strains that didn't exist at the time of the study. Release

And Finally... A 15-year-old developed a vapor-compression refrigeration system requiring minimal power to transport vaccines. More

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.